min Hu

Dr. min Hu

The Second Xiangya Hospital of Central South University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JCJingyao Cai
Jingyao Cai
MHmin Hu
min Hu
ZCZhiyang Chen
Zhiyang Chen
ZLZeng Ling
Zeng Ling
Liver fibrosis occurs in response to any etiology of chronic liver injury. Lack of appropriate clinical intervention will lead to liver cirrhosis or hepatocellular carcinoma (HCC), seriously affecting the quality of life of patients, but the current clinical treatments of liver fibrosis have not been developed yet. Recent studies have shown that hypoxia is a key factor promoting the progression of liver fibrosis. Hypoxia can cause liver fibrosis. Liver fibrosis can, in turn, profoundly further deepen the degree of hypoxia. Therefore, exploring the role of hypoxia in liver fibrosis will help to further understand the process of liver fibrosis, and provide the theoretical basis for its diagnosis and treatment, which is of great significance to avoid further deterioration of liver diseases and protect the life and health of patients. This review highlights the recent advances in cellular and molecular mechanisms of hypoxia in developments of liver fibrosis.

26 February 2024 in Hepatology Communications
Verified
Journal Article
Open access
QLQichen Long
Qichen Long
FLFengming Luo
Fengming Luo
BLBinghui Li
Binghui Li
.L.Ziyang Li
.Ziyang Li
ZGZhe Guo
Zhe Guo
MHmin Hu
min Hu
Metabolic dysfunction–associated steatotic liver disease (MASLD), a replacement of the nomenclature employed for NAFLD, is the most prevalent chronic liver disease worldwide. Despite its high global prevalence, NAFLD is often under-recognized due to the absence of reliable noninvasive biomarkers for diagnosis and staging. Growing evidence suggests that the gut microbiome plays a significant role in the occurrence and progression of NAFLD by causing immune dysregulation and metabolic alterations due to gut dysbiosis. The rapid advancement of sequencing tools and metabolomics has enabled the identification of alterations in microbiome signatures and gut microbiota-derived metabolite profiles in numerous clinical studies related to NAFLD. Overall, these studies have shown a decrease in α-diversity and changes in gut microbiota abundance, characterized by increased levels of Escherichia and Prevotella, and decreased levels of Akkermansia muciniphila and Faecalibacterium in patients with NAFLD. Furthermore, bile acids, short-chain fatty acids, trimethylamine N-oxide, and tryptophan metabolites are believed to be closely associated with the onset and progression of NAFLD. In this review, we provide novel insights into the vital role of gut microbiome in the pathogenesis of NAFLD. Specifically, we summarize the major classes of gut microbiota and metabolic biomarkers in NAFLD, thereby highlighting the links between specific bacterial species and certain gut microbiota-derived metabolites in patients with NAFLD.

13 April 2014 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
DWDebin Wu
Debin Wu
MHMin Hu
Min Hu
LHLi Hong
Li Hong
SHShasha Hong
Shasha Hong
WDWenjuan Ding
Wenjuan Ding
WGWenjun Guo
Wenjun Guo

26 September 2022 in Clinica Chimica Acta
Verified
Journal Article
Open access
ZCZhiyang Chen
Zhiyang Chen
YMYichen Ma
Yichen Ma
JCJingyao Cai
Jingyao Cai
MSMei Sun
Mei Sun
LZLing Zeng
Ling Zeng
MHmin Hu
min Hu
Liver fibrosis is a common pathway in most chronic liver diseases, characterized by excessive extracellular matrix accumulation. Without treatment, fibrosis will ultimately result in cirrhosis, portal hypertension, and even liver failure. It is considered that liver fibrosis is reversible while cirrhosis is not, making it significant to diagnose and evaluate liver fibrogenesis timely. As the gold standard, liver biopsy is imperfect due to its invasiveness and sampling error. Therefore, attempts at uncovering noninvasive tests have become a hot topic in liver fibrosis. Nowadays, as an important category of noninvasive tests, serum biomarkers, which are safer, convenient, repeatable, and more acceptable, are widely discussed and commonly used in clinical practice. Serum biomarkers of liver fibrosis can be divided into class I (direct) and classⅡ (indirect) markers. However, the diagnostic efficiency still varies among studies. This article summarizes the most established and newly discovered serum biomarkers for hepatic fibrogenesis.

20 April 2018 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
PGPing Guo
Ping Guo
HSHong Sun
Hong Sun
YZYuan Zhang
Yuan Zhang
STSean Tighe
Sean Tighe
SCShuangling Chen
Shuangling Chen
YZYingting Zhu
Yingting Zhu
Limbal niche cells located in the limbal Palisades of Vogt are mesenchymal stem cells that reside next to limbal basal epithelial cells. Limbal niche cells are progenitors that express embryonic stem cell markers such as Nanog, Nestin, Oct4, Rex1, Sox2 and SSEA4, mesenchymal cell markers such as CD73, CD90 and CD105, and angiogenesis markers such as Flk‐1, CD31, CD34, VWF, PDGFRβ and α‐SMA, but negative for CD45. In addition, the stemness of limbal niche cells can be maintained during their cell culture in a three‐dimension environment. Furthermore, expanded limbal niche cells have the capability to undergo adipogenesis, chondrogenesis, osteogenesis and endogenesis in vitro, indicating that they are in fact a valuable resource of adult progenitors. Furthermore studies on how the limbal niche cells regulate the aforementioned stemness and corneal fate decision are warranted, as those investigations will shed new light on how mesenchymal progenitors reverse limbal stem cell deficiency and lead to new methods for limbal niche cell treatment.

1 November 2018 in Microbiological Research
Verified
Journal Article
Closed access
LTLi Tan
Li Tan
LBLe Bai
Le Bai
LWLing Wang
Ling Wang
LHLagu He
Lagu He
GLGuangdi Li
Guangdi Li
MHmin Hu
min Hu